NCT02649790 — "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications" trial site landscape

Public-registry site landscape for NCT02649790, “Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications”, a Relapsed/Refractory Multiple Myeloma (RRMM) study sponsored by Karyopharm Therapeutics Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT02649790 (registry record)
Study title	Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Official title	A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Sponsor	Karyopharm Therapeutics Inc
Condition(s)	Relapsed/Refractory Multiple Myeloma (RRMM); Metastatic Colorectal Cancer (mCRC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Phase	PHASE1 / PHASE2
Listed sites	46
Site countries	United States, Canada, China, France, Spain

Patient-friendly overview of this study: eichor.com/study/NCT02649790.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT02649790 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →